The pace of mergers and acquisitions in agribusiness shows no signs of letting up.
2016 on track for the strongest year of foreign acquisitions in the U.S.
Dennis Gartman, the founder and publisher of the Gartman Letter, told CNBC on Wednesday that Monday and Tuesday's market gains could continue for the next couple of weeks.
Dennis Gartman, founder, editor & publisher of The Gartman Letter, comments on Monsanto's decision to reject the Bayer acquisition proposal.
Europe closed sharply up on Tuesday, as sentiment was lifted by positive U.S. trade, and strong gains from banks, insurers and retailers.
Kirsty Wilson, senior analyst at Mergermarket, looks at the potential bidders for U.S. agrichemicals giant Monsanto, including potential interest from China.
Neil Dwane, global strategist at Allianz Global Investors, says many Bayer investors will view the deal negatively as they won't own Monsanto.
John Rountree, managing partner at Novasecta, talks about whether or not the Bayer-Monsanto merger would create more or less innovation and value.
Scott Moeller, director of the M&A Research Centre at Cass Business School, and John Rountree, from Novasecta, discuss the Bayer-Monsanto deal.
Just when you thought the dearth of M&A in Europe was here to stay, Bayer sweeps in with a $62 billion bid for U.S. giant Monsanto.
Bayer's shareholders were not given any indication that the firm would expand into the crop space, explains Sachin Shah from Albert Fried and Company.
Shares of Monsanto advanced 5 percent after German firm Bayer offered to buy the company for $62 billion in cash.
European stocks finished mostly lower on Monday as investors digested a fall in oil prices, mixed data out of the euro zone and the prospect of a U.S. rate hike in June.
New York-based boutique bank Ducera Partners will score a monster payday if $62B the Bayer-Monsanto deal goes through.
U.S. stock index futures pointed to a mixed open on Monday, as oil prices dipped and traders mulled more hints of near-term monetary policy tightening.
Bayer says it has offered $122 per share for Monsanto in an all-cash deal that values the U.S. company at $62 billion.
How tough will it be for Bayer, to convince investors that the Monsanto bid is worth it? Dealreporter assistant editor, Alex Tarrant weighs in.
Julien Jarmoszko, senior research manager at S&P Global Market Intelligence, talks about Bayer's decision to acquire Monsanto.
The pharmaceutical company Bayer has announced plans to acquire American biotech company Monsanto, making an all cash offer of $122 per share.
European stocks finished lower in Thursday as markets around the world digested the latest minutes from the U.S. Federal Reserve.